Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

Next Previous
Trial Profile

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobimetinib (Primary)
  • Indications Erdheim-Chester disease; Langerhans cell histiocytosis; Neurodegenerative disorders; Sarcoma; Sinus histiocytosis
  • Focus Therapeutic Use
  • Acronyms NACHO COBI

Most Recent Events

  • 19 Jun 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
  • 31 Aug 2021 Status changed from not yet recruiting to recruiting.
  • 25 Aug 2020 Planned initiation date changed from 30 Jul 2020 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top